Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fertnstert.2019.08.087 | DOI Listing |
Purpose: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline.
Methods: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data.
Results: Fifty-one articles met eligibility criteria and form the evidentiary basis for the recommendations.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!